Vaccine development and technology for SARS-CoV-2: Current insight

Area of Science:

• Virology
• Immunology
• Pharmaceutical Sciences

Background:

• Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused a global pandemic with challenges in asymptomatic transmission and treatment efficacy.
• Early pandemic responses involved drug treatments with variable safety and efficacy profiles.

Purpose of the Study:

• To critically review and compare the technological formulation, pharmaceutical aspects, safety, efficacy, and immunogenicity of three major COVID-19 vaccines.
• To analyze clinical trial data (Phases 1-3) for Pfizer-BioNTech, Moderna, and Oxford/AstraZeneca vaccines.

Main Methods:

• Comparative analysis of published clinical trial data for Phase 1, 2, and 3 studies.
• Evaluation of vaccine technological platforms, pharmaceutical formulations, and reported safety and immunogenicity profiles.

Main Results:

• All three vaccine candidates exhibited consistent efficacy and good tolerability across clinical trials.
• Identified differences in technological formulation and required storage temperatures, influencing logistical and cost considerations.

Conclusions:

• The reviewed vaccines (Pfizer-BioNTech, Moderna, Oxford/AstraZeneca) show promising efficacy and safety profiles.
• Further long-term studies are essential to fully assess vaccine effectiveness and safety in diverse populations.